Anacor gets $16M to expand GSK R&D pact; Pharmasset shares boosted by positive hep C data; 4SC touts mid-stage cancer study;

@FierceBiotech: Fierce 15 is now live! See the 15 outstanding private biotechs we've selected this year. Report  | Follow @FierceBiotech

@JohnCFierce: One of my favorites is RJ Kirk/Intrexon talking about what he likes in a partner and why he won't work with Big Pharma. Piece | Follow @JohnCFierce

@RyanMFierce: Researchers use neural stem cells (of iPS variety) to study impacts of potential bipolar-disorder treatments. Item | Follow @RyanMFierce

> Anacor has garnered a $5 million upfront payment and the opportunity to earn an extra $11.3 million in research support and milestones from GlaxoSmithKline ($GSK) in exchange for their agreement to expand an R&D collaboration. Through the deal GSK gains the option to extend its rights around the bacterial enzyme target leucyl-tRNA synthetase, as well as to add new programs for tuberculosis and malaria using Anacor's boron chemistry platform. Anacor release

> Shares of Pharmasset got a big boost this morning after the company reported promising mid-stage results for its hepatitis C drug, PSI-7977. All but 2% of the patients in the study had no detectable levels of the virus in their systems after 12 weeks of therapy. Patients received either a 200- or 400-mg dose in the study. Report

> Germany's 4SC AG says its experimental treatment for Hodgkin's lymphoma met the primary endpoint in a mid-stage study. One of every three people in the 33-patient study demonstrated a response to the treatment. The biotech says it is currently in talks with potential collaborators. Story

> Japan's Astellas has landed the global rights for one of Evec's preclinical antibody programs for infectious diseases. Astellas release

Pharma News

@FiercePharma: Biogen takes over marketing JVs that had been selling its MS meds Avonex, Tysabri in 29 countries. Article $BIIB | Follow @FiercePharma

> FDA panels to review bone drug safety. Item

> Remixed Sanofi plans further $2.8B in cost cuts. Story

Biotech IT News

> Merck taps Zymeworks' high-tech antibody shop in $187M deal. News

> Facebook app shows how people swap germs. Piece

> Glencoe, Aridhia team to develop life sciences tech. Story

> Impact Corelab sprouts with clinical tech from Radiant Sage. Piece

> Social networking rallies volunteers in Mayo Clinic study. Story

> MedNet seeks funds to compete in EDC game. Item

Manufacturing News

> Abbott exec tapped for H&P manuf. ops. Report

> Lilly looks eastward with generics deal. Article

> Pharma deal-making minimizes manufacturing. Item

> No penalties for stunning gray price hikes on cancer, anesthesia drugs. Story

> GSK sees resistance to wind turbine project. More

> Vax maker CSL on road to GMP compliance. Article

Biotech Research News

> Researchers find new target for PTSD treatment. Read more

> New drug-discovery center lost in translation. Article

> Researchers report promising new TB vaccine. News

> Stem cells open new front against bipolar disorder. More

> Pimple treatments pocked with poor supporting science. Item

> Get fat stem cells talking to follicles and up sprouts hair. Story

And Finally... Scientists from Scripps have produced the first stem cells from endangered species with an eye to making it possible to improve reproduction and genetic diversity for some species. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.